润燥止痒胶囊联合卤米松治疗原发性皮肤淀粉样变病68例疗效观察

Efficacy Observation for 68 Cases of Primary Localized Cutaneous Amyloidosis Treated with Runzaozhiyang Capsule and Halometasone Cream

目的探讨润燥止痒胶囊口服联合卤米松软膏局部外用治疗原发性皮肤淀粉样变病的临床疗效及安全性。方法将就诊于门诊的129例原发性皮肤淀粉样变病患者随机分为治疗组及对照组,其中治疗组68例给予润燥止痒胶囊口服及卤米松软膏局部外用;对照组61例,仅给予卤米松外用治疗。分别在治疗第2,4和8周末时进行症状评分、疗效判定和安全性评价。结果在治疗的第2周末时,治疗组和对照组有效率分别为47.06%和45.90%,两组差异无统计学意义(P>0.05);在治疗的第4和第8周末时,治疗组有效率为69.12%和83.82%,对照组为55.74%和62.30%,两组差异均有统计学意义(P<0.05)。两组患者仅有轻微不良反应。结论润燥止痒胶囊口服联合卤米松软膏局部外用治疗原发性皮肤淀粉样变病临床疗效较好,中长期使用(1~2个月)疗效优于单用卤米松治疗,且不良反应轻微。

Objective To observe the clinical efficacy and safety of Runzaozhiyang capsule combined with halometasone cream to treat primary localized cutaneous amyloidosis. Methods One hundred and twenty-nine cases of primary localized cutaneous amyloidosis were randomly categorized into treatment group and control group. Sixty- eight cases in treatment group were given Runzaozhiyang capsule for oral use combined with halometasone cream; sixty-one cases in control group was only given halometasone cream. Urge score, efficacy judgement and safety assessment were respectively underwent in the end of second, fourth and eighth week. Results At the end of second week, the effective rates of treatment group and control group were respectively 47.06% and 45.90%. There was no significant difference between them （P 〉 0. 05 ）. However, at the end of fourth and the eighth week, the effective rates of treatment group reached 69. 12% and 83.82% respectively, both of which were significantly higher than those of control group, 55.74% and 62. 30% , at the same period. In addition, little side effects in treatment group and control group were observed during the whole observation period. Conclusion The medium and long-term （ 1 to 2 month period） clinical efficacy of Runzaozhiyang capsule combined with halometasone cream to treat primary localized cutaneous amyloidosis is superior to that only with halometasone cream, and side effects were mild.